logo-loader
RNS
Avacta Group PLC

To Present pre|CISION® Dual Payload Candidate

RNS Number : 6768B
Avacta Group PLC
04 November 2026
 

AVACTA GROUP PLC AVCT Stock | London Stock Exchange

 

   

Avacta Group plc

 

("Avacta" or the "Company")

 

Avacta to Present the pre|CISION® Dual Payload Candidate AVA6207 at the 2026 EORTC-NCI-AACR Symposium

 

 

LONDON and PHILADELPHIA – November 4, 2026 – Avacta Therapeutics (AIM: AVCT, “the Company”, “Avacta”), a life sciences company developing innovative, targeted oncology drugs, today announces it will present AVA6207, its Next-Generation pre|CISION® dual payload peptide-drug conjugate (PDC), in a poster at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, taking place in Barcelona, Spain, from November 18-20.

 

AVA6207 uses the Company’s pre|CISION® PDC technology to deliver two synergistic payloads directly to tumor cells in a single molecule, combining two complementary mechanisms to combat highly resistant cancers. This dual payload molecule functions by inhibiting topoisomerase I (TOP1), inducing severe DNA damage, while simultaneously inhibiting Ataxia Telangiectasia and Rad3-related (ATR) kinase through an ATR inhibitor (ATRi), thus blocking the DNA damage response to prevent cancer cells from repairing TOP1 inhibitor (TOP1i)-induced damage. Combining these two payloads into one pre|CISION® PDC that delivers them directly to the tumor has tremendous potential to improve outcomes in TOP1i-resistant cancers, a growing area of unmet need in oncology.

 

 

Details of the poster presentation

 

Title: AVA6207 is a novel pre|CISION® technology compound delivering complementary TOP1i and ATRi payloads to the tumor microenvironment following FAP cleavage

 

Authors: Victoria Juskaite, Tom Clough, Ellen Watts, et al. and David Jones

Session Title: DNA Repair Modulation (e.g. PARP, CHK, ATR, ATM)

Session Date and Time: Thursday, November 19, 09:00-17:30

Location: Exhibition Hall, Poster Area

Abstract Number: 161

 

 

-Ends-

 

For further information from Avacta, please contact:

 

Avacta Group plc

Christina Coughlin, Chief Executive Officer

https://avacta.com/

via Cohesion Bureau

 

 


 

 

Strand Hanson Limited (Nominated Adviser)

James Harris / Chris Raggett / James Dance

 

 

www.strandhanson.co.uk

 

 

Zeus (Broker)

James Hornigold / George Duxberry (Investment Banking)

 

 

www.zeuscapital.co.uk

 

Cohesion Bureau

Communications / Media / Investors

Chris Maggos

 

avacta@cohesionbureau.com

 

 

 

About Avacta - https://avacta.com/

Avacta Therapeutics is a clinical-stage life sciences company expanding the reach of highly potent cancer therapies through its proprietary pre|CISION® platform. pre|CISION® is a payload delivery system based on a tumor-specific protease (Fibroblast Activation Protein or FAP) that is designed to concentrate highly potent payloads in the tumor microenvironment while sparing normal tissues. Avacta's innovative pre|CISION® peptide drug conjugates (PDC) are a novel entry to the XDC drug class, leveraging the success of antibody drug conjugates with alternative methods of delivery beyond antibodies.

 

Our pre|CISION® PDCs leverage this tumor-specific release mechanism in a small molecule format to provide unique benefits over traditional antibody drug conjugates (ADC), releasing active payload in the tumor and reducing systemic exposure and toxicity which enables dosing to be optimized to deliver the best outcomes for patients. The lead clinical program is AVA6103, a Next Generation FAP-enabled controlled release pre|CISION® version of exatecan that delivers the payload directly in the tumor with limited peripheral blood exposure and is currently in clinical development as a treatment for tumor types sensitive to exatecan including cervical cancer, HR+ breast cancer, small cell lung cancer, gastric cancer, colorectal cancer and pancreatic cancer.

 

About FAP-Exd (AVA6103)

 

AVA6103 is the second clinical candidate and is the first asset in the pipeline based on the Next Generation innovative pre|CISION® controlled release mechanism that provides for prolonged release of payload directly in the tumor, minimizing systemic exposure. AVA6103 is being evaluated in the FOCUS-01 Phase 1 trial (FAP-Exd in Oncologic Cancers with Unmet needS). Preclinical data suggest this approach has optimized payload delivery with a high intratumoral concentration and prolonged exposure of released payload in the tumor, coupled with limited systemic exposure to the released payload. 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCAKNBKOBDDODK
NO INVESTMENT ADVICE

Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.

Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.

This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.

In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.

The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.

Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

FOR OUR FULL DISCLAIMER CLICK HERE

4 min read